1. Signaling Pathways
  2. Neuronal Signaling
  3. Amyloid-β

Amyloid-β

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Amyloid-β Related Products (75):

Cat. No. Product Name Effect Purity
  • HY-B0988
    Deferoxamine mesylate Inhibitor >99.0%
    Deferoxamine mesylate is an iron chelator that binds free iron in a stable complex, preventing it from engaging in chemical reactions.
  • HY-P0128
    Amyloid beta-peptide(25-35) 98.03%
    Amyloid beta-peptide(25-35) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
  • HY-19370
    FPS-ZM1 Inhibitor 99.70%
    FPS-ZM1 is a high-affinity RAGE inhibitor with a Ki of 25 nM.
  • HY-50682
    Azeliragon Inhibitor 98.79%
    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
  • HY-P1363
    Amyloid β-Peptide (1-42) human
    Amyloid β-Peptide (1-42) human is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.
  • HY-N0373
    Licochalcone B Inhibitor 99.41%
    Licochalcone B is an extract from the root of Glycyrrhiza inflate. Licochalcone B inhibits amyloid β (Aβ42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ions.
  • HY-126331
    Glutaminyl Cyclase Inhibitor 4 Inhibitor
    Glutaminyl Cyclase Inhibitor 4 (compound 90) is a potent, selective glutaminyl cyclase (QC) inhibitor with an IC50 of 6.1 nM. Glutaminyl Cyclase Inhibitor 4 is a potent anti-Alzheimer’s agent.
  • HY-117259
    ALZ-801 Inhibitor
    ALZ-801 is an orally available, small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved clinical candidate for the treatment of Alzheimer’s disease.
  • HY-P1061A
    Colivelin TFA
    Colivelin (TFA) is a neuroprotective peptide and activator of STAT3.
  • HY-N0603
    20(S)-Ginsenoside Rg3 Inhibitor >98.0%
    20(S)-Ginsenoside Rg3 is the main component of Red ginseng. Ginsenoside Rg3 inhibits Na+ and hKv1.4 channel with IC50s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits levels, NF-κB activity, and COX-2 expression.
  • HY-P0265
    β-Amyloid 1-40
    β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease.
  • HY-17406
    Tolcapone Inhibitor 99.74%
    Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells.
  • HY-17631A
    Edonerpic maleate Inhibitor 99.40%
    Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides ().
  • HY-N0045
    Ginsenoside Rg1 Inhibitor >98.0%
    Ginsenoside Rg1 is one of the major active components of ginseng. Ginsenoside Rg1 displays promising effects by reducing cerebral levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.
  • HY-P1388A
    β-Amyloid (1-42), rat TFA
    β-Amyloid (1-42), rat TFA is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.
  • HY-10009
    Semagacestat Inhibitor 98.83%
    Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50 of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM.
  • HY-N0009
    Geniposide Antagonist 99.52%
    Geniposide is an iridoid glucoside extracted from Gardenia jasminoides Ellis fruits; exhibits a varity of biological activities such as anti-diabetic, antioxidative, antiproliferative and neuroprotective activities.
  • HY-14537
    Latrepirdine dihydrochloride Inhibitor 99.75%
    Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β () secretion.
  • HY-N0615
    Notoginsenoside R1 Inhibitor
    Notoginsenoside R1, the main bioactive component in panaxnotoginseng, is reported to have some neuronal protective, antihypertensive effects.
  • HY-N0602
    Ginsenoside Rg2 Inhibitor >99.0%
    Ginsenoside Rg2 is one of the major active components of ginseng. Ginsenoside Rg2 acts as a NF-κB inhibitor. Ginsenoside Rg2 also reduces 1-42 accumulation.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.